UPDATE: Gilead Reports Updated Phase 2 Results for Investigational GS-9973, Showed 49% Overall Response Rate with Est. Progression-Free Survival Rate at 24 Weeks 70%

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.